Cargando…
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)
OBJECTIVES: We conducted a subanalysis of data from the multicentre, retrospective observational Nivolumab Japan Real World (CA209-9CR) study to evaluate nivolumab effectiveness and safety in elderly patients (aged ≥75 years) with advanced/metastatic non-small cell lung cancer. MATERIALS AND METHODS...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373314/ https://www.ncbi.nlm.nih.gov/pubmed/32690620 http://dx.doi.org/10.1136/esmoopen-2019-000656 |
_version_ | 1783561479051542528 |
---|---|
author | Okishio, Kyoichi Morita, Ryo Shimizu, Junichi Saito, Haruhiro Sakai, Hiroshi Kim, Young Hak Hataji, Osamu Yomota, Makiko Nishio, Makoto Aoe, Keisuke Kanai, Osamu Kumagai, Toru Kibata, Kayoko Tsukamoto, Hiroaki Oizumi, Satoshi Fujimoto, Daichi Tanaka, Hiroshi Mizuno, Keiko Masuda, Takeshi Kozuki, Toshiyuki Haku, Takashi Suzuki, Hiroyuki Okamoto, Isamu Hoshiyama, Hirotoshi Yada, Nobumichi Ohe, Yuichiro |
author_facet | Okishio, Kyoichi Morita, Ryo Shimizu, Junichi Saito, Haruhiro Sakai, Hiroshi Kim, Young Hak Hataji, Osamu Yomota, Makiko Nishio, Makoto Aoe, Keisuke Kanai, Osamu Kumagai, Toru Kibata, Kayoko Tsukamoto, Hiroaki Oizumi, Satoshi Fujimoto, Daichi Tanaka, Hiroshi Mizuno, Keiko Masuda, Takeshi Kozuki, Toshiyuki Haku, Takashi Suzuki, Hiroyuki Okamoto, Isamu Hoshiyama, Hirotoshi Yada, Nobumichi Ohe, Yuichiro |
author_sort | Okishio, Kyoichi |
collection | PubMed |
description | OBJECTIVES: We conducted a subanalysis of data from the multicentre, retrospective observational Nivolumab Japan Real World (CA209-9CR) study to evaluate nivolumab effectiveness and safety in elderly patients (aged ≥75 years) with advanced/metastatic non-small cell lung cancer. MATERIALS AND METHODS: Medical record data of patients initiating nivolumab treatment between April 2016 and December 2016 were collected using electronic data capture from 23 cancer hospitals in Japan between March 2017 and August 2018. Nivolumab treatment data were collected to investigate the treatment patterns by age group (<75 and ≥75 years), and the effectiveness and safety of nivolumab treatment. RESULTS: Of the 901 patients evaluated, 178 (19.8%) were aged ≥75 years. Overall, patients received a median of five nivolumab treatments regardless of age group. Comparable progression-free survival was observed, with a median of 2.1 months in patients aged <75 years and 2.1 months in patients aged ≥75 years (p=0.5441). No significant differences were found in duration of response, overall response rate or disease control rate between the two age groups. Median overall survival in patients aged <75 and ≥75 years was 14.7 months and 12.3 months, respectively. Grade ≥3 adverse events (AEs) occurred in 29.2% and 28.1% of patients aged <75 and ≥75 years, respectively. Immune-related AEs decreased slightly with increasing age; time to onset and rates of improvement were similar for patients aged <75 and ≥75 years. The most common grade 3–4 AEs were interstitial lung disease in both age groups (4.0% in patients aged <75 years and 2.8% in those aged ≥75 years). Poor performance status was associated with worse outcomes in both age groups. CONCLUSION: Based on Japanese real-world data, the effectiveness and safety of nivolumab were confirmed regardless of age. |
format | Online Article Text |
id | pubmed-7373314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73733142020-07-22 Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) Okishio, Kyoichi Morita, Ryo Shimizu, Junichi Saito, Haruhiro Sakai, Hiroshi Kim, Young Hak Hataji, Osamu Yomota, Makiko Nishio, Makoto Aoe, Keisuke Kanai, Osamu Kumagai, Toru Kibata, Kayoko Tsukamoto, Hiroaki Oizumi, Satoshi Fujimoto, Daichi Tanaka, Hiroshi Mizuno, Keiko Masuda, Takeshi Kozuki, Toshiyuki Haku, Takashi Suzuki, Hiroyuki Okamoto, Isamu Hoshiyama, Hirotoshi Yada, Nobumichi Ohe, Yuichiro ESMO Open Original Research OBJECTIVES: We conducted a subanalysis of data from the multicentre, retrospective observational Nivolumab Japan Real World (CA209-9CR) study to evaluate nivolumab effectiveness and safety in elderly patients (aged ≥75 years) with advanced/metastatic non-small cell lung cancer. MATERIALS AND METHODS: Medical record data of patients initiating nivolumab treatment between April 2016 and December 2016 were collected using electronic data capture from 23 cancer hospitals in Japan between March 2017 and August 2018. Nivolumab treatment data were collected to investigate the treatment patterns by age group (<75 and ≥75 years), and the effectiveness and safety of nivolumab treatment. RESULTS: Of the 901 patients evaluated, 178 (19.8%) were aged ≥75 years. Overall, patients received a median of five nivolumab treatments regardless of age group. Comparable progression-free survival was observed, with a median of 2.1 months in patients aged <75 years and 2.1 months in patients aged ≥75 years (p=0.5441). No significant differences were found in duration of response, overall response rate or disease control rate between the two age groups. Median overall survival in patients aged <75 and ≥75 years was 14.7 months and 12.3 months, respectively. Grade ≥3 adverse events (AEs) occurred in 29.2% and 28.1% of patients aged <75 and ≥75 years, respectively. Immune-related AEs decreased slightly with increasing age; time to onset and rates of improvement were similar for patients aged <75 and ≥75 years. The most common grade 3–4 AEs were interstitial lung disease in both age groups (4.0% in patients aged <75 years and 2.8% in those aged ≥75 years). Poor performance status was associated with worse outcomes in both age groups. CONCLUSION: Based on Japanese real-world data, the effectiveness and safety of nivolumab were confirmed regardless of age. BMJ Publishing Group 2020-07-20 /pmc/articles/PMC7373314/ /pubmed/32690620 http://dx.doi.org/10.1136/esmoopen-2019-000656 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Okishio, Kyoichi Morita, Ryo Shimizu, Junichi Saito, Haruhiro Sakai, Hiroshi Kim, Young Hak Hataji, Osamu Yomota, Makiko Nishio, Makoto Aoe, Keisuke Kanai, Osamu Kumagai, Toru Kibata, Kayoko Tsukamoto, Hiroaki Oizumi, Satoshi Fujimoto, Daichi Tanaka, Hiroshi Mizuno, Keiko Masuda, Takeshi Kozuki, Toshiyuki Haku, Takashi Suzuki, Hiroyuki Okamoto, Isamu Hoshiyama, Hirotoshi Yada, Nobumichi Ohe, Yuichiro Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title_full | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title_fullStr | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title_full_unstemmed | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title_short | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
title_sort | nivolumab treatment of elderly japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (ca209-9cr) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373314/ https://www.ncbi.nlm.nih.gov/pubmed/32690620 http://dx.doi.org/10.1136/esmoopen-2019-000656 |
work_keys_str_mv | AT okishiokyoichi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT moritaryo nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT shimizujunichi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT saitoharuhiro nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT sakaihiroshi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT kimyounghak nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT hatajiosamu nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT yomotamakiko nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT nishiomakoto nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT aoekeisuke nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT kanaiosamu nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT kumagaitoru nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT kibatakayoko nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT tsukamotohiroaki nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT oizumisatoshi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT fujimotodaichi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT tanakahiroshi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT mizunokeiko nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT masudatakeshi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT kozukitoshiyuki nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT hakutakashi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT suzukihiroyuki nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT okamotoisamu nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT hoshiyamahirotoshi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT yadanobumichi nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr AT oheyuichiro nivolumabtreatmentofelderlyjapanesepatientswithnonsmallcelllungcancersubanalysisofarealworldretrospectiveobservationalstudyca2099cr |